Research

SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT)

Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission

SAINT Project Logo
Duration
14/05/2020 - 30/08/2020
Coordinator
Carlos Chaccour
Funded by
ISGlobal, Clinica Universidad de Navarra, IDIFARMA

Ivermectin is a widely used drug for the treatment and control of certain neglected tropical diseases. The drug has an excellent safety profile, with more than 2.5 billion doses distributed in the last 30 years. It has proven activity against SARS-CoV-2 in vitro.

For this pilot trial we propose to test the potential of ivermectin to reduce the transmission of the virus. If the results are positive this could be quickly scaled given the known safety profile and robust drug supply.


Help Us Do Research on COVID-19!

If you suspect you might have COVID-19, and:

  • you have symptoms compatible with the disease within the last 48 hours, such as fever, dry cough, headache, and general malaise;
  • you are between 18 and 59 years old; and
  • you live in the Pamplona Basin.

Please, call to the telephone number 628 659 003. In case you are a potential candidate, we will lead you to the ER of the Clínica Universidad de Navarra for a formal visit.

We will stop the new coronavirus together!


More Information:

A Project by:

   

Supported by:

Our Team

Project Coordinator

ISGlobal Team

Other projects

See Past Projects

COMBACTE

Combating Bacterial Resistance In Europe

Xpatial-TB

Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique

AVATAR

Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.

COVID-PREG

Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy